Group 1 - The article discusses the investment opportunities in the biotech sector, particularly focusing on BioMarin and its hemophilia drug Roctavian, which is linked to the Prescription Drug User Fee Act (PDUFA) date [2] - The author emphasizes the importance of catalysts for both novice and experienced biotech investors, providing insights into product sales forecasts and integrated financial statements [2] - The article highlights the expertise of the author, who has over five years of experience in biotech consulting and has prepared detailed reports on more than 1,000 companies [2]

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1][2] Zacks Style Scores - Zacks Style Scores are indicators that assist investors in selecting stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [3] - The Value Score focuses on identifying undervalued stocks using ratios like P/E, PEG, and Price/Sales [4] - The Growth Score emphasizes a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow [5] - The Momentum Score identifies optimal times to invest based on price trends and earnings estimate changes [6] - The VGM Score combines all three styles, providing a comprehensive rating based on value, growth, and momentum [7] Zacks Rank - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors in portfolio creation [8] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [9] - There are over 800 stocks rated 1 or 2, which can be overwhelming for investors [10] Investment Strategy - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [11] - Stocks with a 3 (Hold) rank should also have A or B Scores to ensure potential upside [11] - The direction of earnings estimate revisions is crucial; stocks with lower ranks and declining forecasts pose higher risks [12][13] Company Spotlight: BioMarin Pharmaceutical (BMRN) - BioMarin Pharmaceutical Inc. specializes in developing treatments for severe medical conditions, primarily in children [14] - BMRN holds a 3 (Hold) Zacks Rank and a VGM Score of A, with a Value Style Score of B, indicating attractive valuation metrics such as a forward P/E ratio of 19.13 [15] - Recent analyst revisions have increased earnings estimates for fiscal 2024, with the Zacks Consensus Estimate rising by $0.02 to $3.27 per share, alongside an average earnings surprise of 28.7% [15] - With a solid Zacks Rank and strong Value and VGM Style Scores, BMRN is recommended for investors' consideration [16]

Group 1 - BioMarin Pharmaceutical Inc. will present at three upcoming investor conferences, including the UBS Global Healthcare Conference, Jefferies London Healthcare Conference, and the Evercore ISI HealthCONx Conference [2][1] - An audio webcast of the presentations will be available live and archived on the company's website for a limited time [2][3] - BioMarin is a global biotechnology company focused on developing medicines for rare genetic conditions, with a strong pipeline and eight commercial therapies [3]

Core Insights - Zacks Premium provides tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores serve as complementary indicators to the Zacks Rank, aiding in stock selection [2] Zacks Style Scores Overview - Stocks are rated from A to F based on value, growth, and momentum qualities, with A indicating the highest potential for outperformance [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5] Value Score - Focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - Concentrates on a company's financial health and future growth potential, analyzing projected and historical earnings, sales, and cash flow [4] Momentum Score - Targets stocks with upward or downward price trends, utilizing metrics like one-week price change and monthly earnings estimate changes [4] VGM Score - Combines all three Style Scores to identify stocks with the best value, growth forecasts, and momentum [5] Zacks Rank Integration - The Zacks Rank is a proprietary model based on earnings estimate revisions, which helps investors build successful portfolios [6] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +25.41%, significantly outperforming the S&P 500 [7] Stock Selection Strategy - Investors should prioritize stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal success [8] - Stocks with lower ranks but high Style Scores may still carry risks due to downward earnings outlooks [9] Company Spotlight: BioMarin Pharmaceutical (BMRN) - BioMarin focuses on developing treatments for severe medical conditions, particularly in children, and currently holds a 3 (Hold) Zacks Rank with a VGM Score of A [10] - The company has a forward P/E ratio of 20.18, indicating attractive valuation metrics for value investors [10] - Recent analyst revisions have increased the earnings estimate for fiscal 2024 to $3.27 per share, with an average earnings surprise of 28.7% [11]

Core Viewpoint - BioMarin Pharmaceutical (BMRN) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [2][4]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Business Improvement Indicators - The upgrade in BioMarin's rating reflects an improvement in the company's underlying business, which is expected to drive stock appreciation [5]. - BioMarin is projected to earn $3.27 per share for the fiscal year ending December 2024, representing a year-over-year increase of 57.2% [8]. Earnings Estimate Revisions - Over the past three months, the Zacks Consensus Estimate for BioMarin has increased by 23.6%, indicating a positive trend in earnings estimates [8]. - The Zacks Rank system classifies stocks based on earnings estimate revisions, with only the top 20% of stocks receiving a 'Strong Buy' or 'Buy' rating, suggesting potential for market-beating returns [9][10].

Core Insights - BioMarin Pharmaceutical (BMRN) is currently viewed as a more attractive investment compared to Incyte (INCY) for those seeking undervalued stocks in the Medical - Biomedical and Genetics sector [1] Valuation Metrics - BMRN has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while INCY has a Zacks Rank of 3 (Hold) [3] - BMRN's forward P/E ratio is 20.37, significantly lower than INCY's forward P/E of 54.33, suggesting BMRN is more reasonably priced [5] - The PEG ratio for BMRN is 0.50, indicating better value relative to its expected earnings growth compared to INCY's PEG ratio of 2.48 [5] - BMRN's P/B ratio stands at 2.34, while INCY's P/B ratio is 4.62, further supporting BMRN's valuation advantage [6] - Based on these metrics, BMRN has earned a Value grade of B, whereas INCY has a Value grade of C [6] Conclusion - Overall, BMRN is positioned as the superior value option due to its solid earnings outlook and favorable valuation metrics compared to INCY [7]

Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market ______________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ Form 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG ...

BioMarin Pharmaceutical (BMRN) reported adjusted earnings per share of 91 cents in third-quarter 2024, beating the Zacks Consensus Estimate of 78 cents. Quarterly earnings rose 98% year over year, driven by higher sales, partially offset by rising operating expenses. Total revenues were $746 million in the reported quarter, up 28% year over year on a reported basis and 32% on a constant-currency basis. Strong sales of Voxzogo drove this upside. The top line beat the Zacks Consensus Estimate of $707 million. ...

Financial Data and Key Metrics Changes - BioMarin reported record financial results with revenues reaching $746 million, a 28% increase compared to the same period in 2023 [5][19] - Non-GAAP diluted earnings per share increased nearly double compared to Q3 2023, totaling $0.91, while GAAP diluted earnings per share increased 162% to $0.55 [25][26] - Operating cash flows totaled $221 million in Q3, an increase of 63% compared to the same quarter last year [26][27] Business Line Data and Key Metrics Changes - VOXZOGO revenue grew 54% year-over-year, reaching $190 million in Q3, driven by new patient starts and expanded indications [8][19] - Enzyme Therapies portfolio generated $509 million in revenue, representing a 27% year-over-year increase, with ALDURAZYME being a significant contributor [20][13] - NAGLAZYME experienced a 21% year-over-year growth, while PALYNZIQ revenues increased 15% year-over-year [21][78] Market Data and Key Metrics Changes - The U.S. and EU markets comprise approximately 32% of the global total addressable patient population for achondroplasia, with 68% insulated from mid-term competitive threats [11][12] - BioMarin aims to expand VOXZOGO into more than 20 additional markets by 2027, with approximately 90% of the global achondroplasia patient population outside the U.S. [34] Company Strategy and Development Direction - The company is implementing a new corporate strategy focused on innovation, growth, and value commitment, structuring around new business units [6][30] - BioMarin is targeting approximately $4 billion in total revenues by 2027 and aims for a mid-teen compound annual growth rate for total revenues through 2034 [15][30] - The company plans to vigorously defend its intellectual property and leverage its global capabilities to maintain market leadership [12][62] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustained leadership across the Skeletal Conditions franchise and the long-term growth potential of the Enzyme Therapies portfolio [9][13] - The company reaffirmed its long-term guidance despite increased competition, indicating that its initial guidance was not conservative [71][72] Other Important Information - BioMarin settled $495 million of convertible debt maturity in cash during Q3, retiring approximately 4 million potentially dilutive shares [27] - The company has a strong balance sheet with total cash and investments of approximately $1.5 billion at the end of Q3 2024 [27] Q&A Session Summary Question: What phase of development would be ideal for BioMarin at this stage in the pipeline's maturity? - Management indicated a focus on transactions less than $1.5 billion, leveraging their scientific capabilities and identifying earlier transactions to bolster research efforts [52][55] Question: Can you walk through the development strategy for BMN 333? - Management expressed excitement about BMN 333, highlighting its potential to increase pharmacokinetic exposure and efficacy in treating genetic skeletal disorders [58][60] Question: What is driving the increase in the ERT business growth? - The growth is primarily driven by PALYNZIQ, with strong patient uptake in the U.S. and new initiatives aimed at high-yield patient finding and geographic expansion [76][78] Question: Can you provide more color on the competitive positioning of PALYNZIQ? - Management believes the addition of new agents in the PKU space will benefit patients by providing more treatment options, and they are developing a next-generation PALYNZIQ [92][94] Question: What is the status of the transition to full approval for VOXZOGO? - Management is committed to measuring final adult height on patients from the pivotal study and is focused on converting to full approval [90][91]

BioMarin Pharmaceutical (BMRN) reported $745.74 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 28.3%. EPS of $0.91 for the same period compares to $0.46 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $706.95 million, representing a surprise of +5.49%. The company delivered an EPS surprise of +16.67%, with the consensus EPS estimate being $0.78. While investors scrutinize revenue and earnings changes year-over-year and how they ...